Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205


Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA.

J Nucl Med. 2004 Jan;45(1):129-37.


Efforts to control the errant products of a targeted in vivo generator.

Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA.

Cancer Res. 2005 Jun 1;65(11):4888-95.


Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA.

Clin Cancer Res. 2004 Oct 15;10(20):6985-92.


Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.

Schwartz J, Jaggi JS, O'Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL.

Phys Med Biol. 2011 Feb 7;56(3):721-33. doi: 10.1088/0031-9155/56/3/012. Epub 2011 Jan 10.


Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA.

J Nucl Med. 1999 Jan;40(1):166-76.


Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters.

Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA.

J Am Soc Nephrol. 2005 Sep;16(9):2677-89. Epub 2005 Jun 29.


Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.

Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, Theodore LJ, Plascjak PS, Eckelman WC, Waldmann TA, Pastan I, Paik CH, Brechbiel MW, Carrasquillo JA.

Clin Cancer Res. 2004 May 1;10(9):3137-46.


LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.

Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, Rondinone AJ, Standaert RF, Mirzadeh S.

Bioconjug Chem. 2011 Apr 20;22(4):766-76. doi: 10.1021/bc100574f. Epub 2011 Mar 24.


Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR.

J Nucl Med. 2006 Jun;47(6):912-8.


Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.

Muraszko K, Sung C, Walbridge S, Greenfield L, Dedrick RL, Oldfield EH, Youle RJ.

Cancer Res. 1993 Aug 15;53(16):3752-7.


Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.

Clin Cancer Res. 2004 Jul 1;10(13):4489-97.


Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ.

J Allergy Clin Immunol. 2001 Aug;108(2):250-7.


Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.

Uckun FM, Yanishevski Y, Tumer N, Waurzyniak B, Messinger Y, Chelstrom LM, Lisowski EA, Ek O, Zeren T, Wendorf H, Langlie MC, Irvin JD, Myers DE, Fuller GB, Evans W, Gunther R.

Clin Cancer Res. 1997 Mar;3(3):325-37.


Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.

Blood. 2002 Aug 15;100(4):1233-9.


Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.

J Nucl Med. 2009 Jul;50(7):1153-60. doi: 10.2967/jnumed.109.062604. Epub 2009 Jun 12.


Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J.

J Nucl Med. 2006 Feb;47(2):247-55.


Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Nov;46(11):1907-15.


Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.

Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.

Nucl Med Biol. 2006 Nov;33(8):1065-72. Epub 2006 Oct 4.


Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.

Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, Essler M.

Clin Cancer Res. 2008 Jun 1;14(11):3555-61. doi: 10.1158/1078-0432.CCR-07-4647.

Supplemental Content

Support Center